OncoMatch/Clinical Trials/NCT06826118
Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma
Is NCT06826118 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Axicabtagene Ciloleucel for lymphoma.
Treatment: Axicabtagene Ciloleucel — A prospective collection of data on the treatment of Chinese patients with relapsed/refractory follicular lymphoma (FL) using Axicabtagene Ciloleucel Injection, and evaluation of the efficacy and safety of Axicabtagene Ciloleucel Injection in this treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-CD20 monoclonal antibody in combination with an alkylating agent
Prior therapy must include: anti-CD20 monoclonal antibody in combination with an alkylating agent (anti-CD20 monoclonal antibody monotherapy is not eligible as a line of therapy for eligibility)
Cannot have received: CD19-targeted therapy
Previous CD19-targeted therapy
Cannot have received: chimeric antigen receptor cell therapy or other genetically modified T-cell therapy
Previous chimeric antigen receptor cell therapy or other genetically modified T-cell therapy
Cannot have received: autologous hematopoietic stem cell transplantation
Autologous Hematopoietic Stem Cell Transplantation Within 6 Weeks Prior to Scheduled Infusion
Cannot have received: allogeneic hematopoietic stem cell transplantation
Has performed allogeneic hematopoietic stem cell transplants
Lab requirements
Blood counts
ANC ≥ 1.0×10^9/L; Platelet count ≥ 75×10^9/L; Absolute lymphocyte count ≥ 0.1×10^9/L
Kidney function
serum creatinine ≤ 1.5 x ULN or creatinine clearance (CCr) ≥ 60 mL/min (Cockcroft-Gault)
Liver function
total bilirubin (TBIL) ≤ 1.5 x ULN (except Gilbert's syndrome); ALT and AST ≤ 2.5 x ULN
Cardiac function
ejection fraction ≥ 50%, absence of pericardial effusion (ECHO), absence of clinically significant cardiac arrhythmia
Adequate renal, hepatic, pulmonary, and cardiac function, defined as: 1) total bilirubin (TBIL) ≤ 1.5 x ULN (except Gilbert's syndrome); 2) ALT and AST ≤ 2.5 x ULN; 3) serum creatinine ≤ 1.5 x ULN or creatinine clearance (CCr) ≥ 60 mL/min (Cockcroft-Gault); 4) cardiac ejection fraction ≥ 50%, absence of pericardial effusion (ECHO), and absence of clinically significant cardiac arrhythmia; 5) baseline transcutaneous oxygen saturation > 92% under room ventilation; 6) absence of clinically significant chest pain; and 7) absence of clinically significant pleural effusion.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06826118 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CD19-targeted therapy, chimeric antigen receptor cell therapy or other genetically modified T-cell therapy, autologous hematopoietic stem cell transplantation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify